Form 4: Traws Pharma Director Awarded Equity Compensation

Traws Pharma director Jack E. Stover received an award of 6,157 restricted stock units and 24,629 stock options on December 12, 2025.

Summary

• Jack E. Stover, a Director of Traws Pharma, Inc. (TRAW), was granted equity awards on December 12, 2025.
• The awards include 6,157 restricted stock units (RSUs) and 24,629 stock options.
• Each restricted stock unit will convert into one share of common stock.
• The RSUs and stock options are scheduled to vest 100% on the first anniversary of the grant date, December 12, 2026.
• The stock options have an exercise price of $2.33 per share and an expiration date of December 12, 2035.
• Following these transactions, Jack E. Stover beneficially owns 6,165 shares of common stock directly and 24,629 stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director receiving equity awards generally indicates alignment with shareholder interests and confidence in the company's future, although it is a routine compensation event.

Positives

• The award of restricted stock units and stock options to a director increases their direct equity stake and aligns their interests with those of shareholders.
• Equity compensation is a standard practice to incentivize long-term performance and retention of key personnel.

Future Outlook

The restricted stock units and stock options are set to vest on December 12, 2026, which will increase the director's exercisable equity holdings at that time.

Industry Context

Equity awards, such as restricted stock units and stock options, are a common component of executive and director compensation packages across various industries, particularly in the pharmaceutical sector, to align leadership incentives with company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with long-term shareholder value through equity ownership.
• Management/Employees: Reinforces the company's compensation strategy for key personnel.

Next Steps

• The restricted stock units will convert into common stock upon vesting on December 12, 2026.
• The stock options will become exercisable upon vesting on December 12, 2026, and can be exercised until their expiration date of December 12, 2035.

Key Dates

Keywords

Traws Pharma, TRAW, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Award